Help us: Donate
Follow us on:



Senolytics Alleviate Age‐Related Cognitive Decline

Senescent cells in the brain harm cognitive function.

Missing pieces of the brainMissing pieces of the brain

A new study by a team of researchers, including Dr. Kirkland of Mayo Clinic, shows the effect of whole-body senolytic treatment on the health and function of the brain.

This follows up on previous Mayo Clinic research led by Dr. James Kirkland. That experiment treated mice with a combination of the cancer drug dasatinib and the dietary supplement quercetin, and the results suggested that this combination has a senolytic effect, meaning that it can destroy senescent cells.

To test if senolytics would have any influence on age-related cognitive decline, the researchers opted to work with INK-ATTAC mice, which are specially engineered to destroy populations of senescent cells (specifically p16Ink4a‐positive senescent cells) upon exposure to the drug AP20187. Having this chemical trigger to kill senescent cells allows researchers to reliably observe what happens when populations of senescent cells are destroyed.

Upon examining the hippocampi of young and old mice, they discovered there was an age-dependent increase in the numbers of p16Ink4a-expressing senescent cells, and microglia and oligodendrocyte progenitor cells were shown to have the highest p16Ink4a activity.

The researchers then treated the mice with either AP20187 or a combination of dasatinib and quercetin. They discovered that both forms of treatment decreased p16Ink4a-expressing microglial cells, resulting in reduced microglial activation and a reduction of the SASP, the cocktail of inflammatory signals secreted by senescent cells.

In addition, both treatments improved cognitive function in the aged mice.

Cellular senescence is characterized by an irreversible cell cycle arrest and a pro‐inflammatory senescence‐associated secretory phenotype (SASP), which is a major contributor to aging and age‐related diseases. Clearance of senescent cells has been shown to improve brain function in mouse models of neurodegenerative diseases. However, it is still unknown whether senescent cell clearance alleviates cognitive dysfunction during the aging process. To investigate this, we first conducted single‐nuclei and single‐cell RNA‐seq in the hippocampus from young and aged mice. We observed an age‐dependent increase in p16Ink4a senescent cells, which was more pronounced in microglia and oligodendrocyte progenitor cells and characterized by a SASP. We then aged INK‐ATTAC mice, in which p16Ink4a‐positive senescent cells can be genetically eliminated upon treatment with the drug AP20187 and treated them either with AP20187 or with the senolytic cocktail Dasatinib and Quercetin. We observed that both strategies resulted in a decrease in p16Ink4a exclusively in the microglial population, resulting in reduced microglial activation and reduced expression of SASP factors. Importantly, both approaches significantly improved cognitive function in aged mice. Our data provide proof‐of‐concept for senolytic interventions’ being a potential therapeutic avenue for alleviating age‐associated cognitive impairment.


These findings suggest that an effective senolytic treatment could improve brain health and reduce age-related cognitive decline. While this research was in mice, there are multiple senolytic drugs poised to enter human trials this year. Given that senescent cell accumulation is a likely reason why humans, mice and most other species age, there is reason to be optimistic that the benefits of removing these harmful cells may well translate to humans too.

2021 is primed to be an exciting year in aging research, especially given the number of therapies entering the clinic. We discuss some of the companies that we are watching closely this year here.

Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension: YouTube Facebook Twitter Instagram Instagram Discord
Thank You!

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. Jerry Irwin
    February 2, 2021

    What combination were they using?
    Was it 100 mg dasatinib and 1,250 mg quercitin 3 consecutive days and then the same dosage the following week and the week after?

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.